3. ๊ท€๊ฐ€ ํŠธ์ด๋Š” ์˜์–ด

24.09.27 Pfizer Advances Development of Once-Daily Weight Loss Pill

ํ•˜ ๋Œ€ํ‘œ 2024. 10. 9. 04:02

Pfizer is moving forward with a once-daily version of its weight loss pill, danuglipron, after promising early-stage trial results.

ํ™”์ด์ž๊ฐ€ ์ดˆ๊ธฐ ๋‹จ๊ณ„ ์ž„์ƒ ์‹œํ—˜์—์„œ ๊ธ์ •์ ์ธ ๊ฒฐ๊ณผ๋ฅผ ์–ป์€ ์ฒด์ค‘ ๊ฐ๋Ÿ‰์ œ ๋‹ค๋ˆ„๊ธ€๋ฆฌํ”„๋ก ์˜ 1์ผ 1ํšŒ ๋ณต์šฉ ๋ฒ„์ „ ๊ฐœ๋ฐœ์„ ์ถ”์ง„ํ•œ๋‹ค.

* pill : ์•Œ์•ฝ, ์ •์ œ

* promising : ์žฅ๋ž˜๊ฐ€ ์ด‰๋ง๋˜๋Š”, ์ „๋„์œ ๋งํ•œ

* trial : (์ƒํ’ˆโˆ™์„œ๋น„์Šค ๋“ฑ์˜) ์‹œํ—˜ ์‚ฌ์šฉ (๊ธฐ๊ฐ„), ์ฒดํ—˜ (๊ธฐ๊ฐ„)

โ€‹

The company plans to conduct additional studies in the latter half of the year to determine optimal dosing.

ํšŒ์‚ฌ๋Š” ์˜ฌํ•ด ํ•˜๋ฐ˜๊ธฐ์— ์ตœ์  ๋ณต์šฉ๋Ÿ‰์„ ๊ฒฐ์ •ํ•˜๊ธฐ ์œ„ํ•œ ์ถ”๊ฐ€ ์—ฐ๊ตฌ๋ฅผ ์ง„ํ–‰ํ•  ๊ณ„ํš์ด๋‹ค.

* conduct : <์—ฐ๊ตฌโˆ™์—…๋ฌด ๋“ฑ>์„ ์‹ค์‹œํ•˜๋‹ค, ์ˆ˜ํ–‰ํ•˜๋‹ค, <ํšŒ์‚ฌ ๋“ฑ>์„ ์šด์˜ํ•˜๋‹ค

* the latter : (๋‘˜ ์ค‘์—์„œ) ํ›„์ž, ๋’ค์˜ ๊ฒƒ[์‚ฌ๋žŒ]

* determine : (๊ณต์‹์ ์œผ๋กœ) โ‹ฏ์„ ๊ฒฐ์ •ํ•˜๋‹ค, ์ •ํ•˜๋‹ค

* optimal : ์ตœ์ ์˜, ๊ฐ€์žฅ ๋ฐ”๋žŒ์งํ•œ

* dose : <์‚ฌ๋žŒโˆ™๋™๋ฌผ>์—๊ฒŒ ํˆฌ์•ฝํ•˜๋‹ค, ์•ฝ์„ ๋ณต์šฉ์‹œํ‚ค๋‹ค

โ€‹

This development comes after setbacks with previous versions of the drug, including tolerability issues with a twice-daily formulation.

โ€‹์ด๋Š” ๊ธฐ์กด์˜ 1์ผ 2ํšŒ ๋ณต์šฉ ๋ฒ„์ „์˜ ๋‚ด์•ฝ์„ฑ ๋ฌธ์ œ ๋“ฑ ๋‚œ๊ด€์— ๋ด‰์ฐฉํ•œ ์ดํ›„์— ๋‚˜์˜จ ๊ฒƒ์ด๋‹ค.

* come after something : <๋•Œโˆ™์‚ฌ๊ฑด ๋“ฑ์ด> โ‹ฏ์˜ ํ›„์— ์˜ค๋‹ค, โ‹ฏ์˜ ํ›„์— ๋ฐœ์ƒ๋‚˜๋‹ค

* setback : ์ขŒ์ ˆ

* tolerability : ์ฐธ์„ ์ˆ˜ ์žˆ์Œ, (๊ฑด๊ฐ• ์ƒํƒœ๊ฐ€) ๊ดœ์ฐฎ์Œ

* formulation : (์•ฝ ๋“ฑ์˜) ์กฐ์ œ

โ€‹

The pharmaceutical giant aims to compete in the rapidly growing market for GLP-1 agonists, a class of drugs used for weight loss and diabetes treatment.

์ด ๊ฑฐ๋Œ€ ์ œ์•ฝ ํšŒ์‚ฌ๋Š” ์ฒด์ค‘ ๊ฐ๋Ÿ‰ ๋ฐ ๋‹น๋‡จ๋ณ‘ ์น˜๋ฃŒ์— ์‚ฌ์šฉ๋˜๋Š” ์•ฝ๋ฌผ์ธ GLP-1 ์ˆ˜์šฉ์ฒด ์ž‘์šฉ์ œ ์‹œ์žฅ์ด ๊ธ‰์„ฑ์žฅํ•˜๊ณ  ์žˆ๋Š” ๊ฐ€์šด๋ฐ ๊ฒฝ์Ÿ๋ ฅ์„ ํ™•๋ณดํ•˜๋Š” ๊ฒƒ์„ ๋ชฉํ‘œ๋กœ ํ•˜๊ณ  ์žˆ๋‹ค.

* pharmaceutical : ์ œ์•ฝ์˜, ์•ฝ์ œ์˜

* aim to do something : โ‹ฏํ•˜๋Š” ๊ฒƒ์„ ๋ชฉํ‘œ๋กœ ํ•˜๋‹ค, โ‹ฏํ•  ์ƒ๊ฐ์ด๋‹ค

* agonists : ์ž‘์šฉ์ œ

* a class of drugs used for weight loss : ์ฒด์ค‘ ๊ฐ๋Ÿ‰์— ์‚ฌ์šฉ๋˜๋Š” ์•ฝ๋ฌผ

โ€‹

Despite facing challenges in this space, Pfizer remains committed to obesity as a key therapeutic area.

ํ•ด๋‹น ๋ถ„์•ผ์—์„œ ์—ฌ๋Ÿฌ ๋‚œ๊ด€์— ๋ด‰์ฐฉํ–ˆ์ง€๋งŒ, ํ™”์ด์ž๋Š” ๋น„๋งŒ์„ ํ•ต์‹ฌ ์น˜๋ฃŒ ๋ถ„์•ผ๋กœ ์‚ผ์•„ ๊ณ„์† ๋…ธ๋ ฅํ•˜๊ณ  ์žˆ๋‹ค.

* face a โ€Šchallenge : ๋‚œ๊ด€์— ์ง๋ฉดํ•˜๋‹ค

* commit : (ํŠน์ • ๋ชฉ์ ์—) <์‹œ๊ฐ„โˆ™๋ˆโˆ™์‚ฌ๋žŒ ๋“ฑ>์„ ํˆฌ์ž…ํ•˜๋‹ค

* obesity : ๋น„๋งŒ

* therapeutic : ์น˜๋ฃŒ์ ์ธ, ์น˜๋ฃŒ์— ๋„์›€์ด ๋˜๋Š”

โ€‹

The company is exploring various approaches, including potential acquisitions of earlier-stage weight loss drugs.

โ€‹ํ™”์ด์ž๋Š” ๋ณด๋‹ค ์ดˆ๊ธฐ ๋‹จ๊ณ„์˜ ์ฒด์ค‘ ๊ฐ๋Ÿ‰ ์•ฝ๋ฌผ ์ธ์ˆ˜ ๊ฐ€๋Šฅ์„ฑ ๋“ฑ ๋‹ค์–‘ํ•œ ๋ฐฉ์•ˆ๋„ ๋ชจ์ƒ‰ํ•˜๊ณ  ์žˆ๋‹ค.

* explore : <์ƒ๊ฐโˆ™๋ฐฉ๋ฒ• ๋“ฑ>์„ ํƒ๊ตฌํ•˜๋‹ค, ๊ฒ€ํ† ํ•˜๋‹ค, ์—ฐ๊ตฌํ•˜๋‹ค

* potential : ์ž ์žฌ์ ์ธ

* acquisition : ํš๋“, ์ž…์ˆ˜, ์ธ์ˆ˜

โ€‹

Pfizer's efforts align with the broader industry trend of developing oral alternatives to injectable weight loss medications.

ํ™”์ด์ž์˜ ์ด๋Ÿฌํ•œ ๋…ธ๋ ฅ์€ ์ฃผ์‚ฌ์ œ ํ˜•ํƒœ์˜ ์ฒด์ค‘ ๊ฐ๋Ÿ‰ ์•ฝ๋ฌผ์„ ๋Œ€์‹ ํ•  ๊ฒฝ๊ตฌ์šฉ ๋Œ€์ฒด์ œ ๊ฐœ๋ฐœ์ด๋ผ๋Š” ์—…๊ณ„์˜ ๋ณด๋‹ค ํฐ ํ๋ฆ„๊ณผ ์ผ์น˜ํ•œ๋‹ค.

* align : ์ผ๋ ฌ์ด ๋˜๋‹ค, ๋‚˜๋ž€ํžˆ ๋†“์ด๋‹ค

* oral : ์ž…์˜, ๊ตฌ๊ฐ•์˜

* alternative : ๋Œ€์•ˆ

* injectable : <์•ฝ๋ฌผ์ด> ์ฃผ์‚ฌ ๊ฐ€๋Šฅํ•œ

* medication : ์•ฝ, ์•ฝ๋ฌผ

โ€‹

These pills could offer greater convenience for patients and ease manufacturing challenges.

์ด๋Ÿฌํ•œ ์•Œ์•ฝ์€ ํ™˜์ž๋“ค์—๊ฒŒ ๋ณด๋‹ค ๋†’์€ ํŽธ๋ฆฌ์„ฑ์„ ์ œ๊ณตํ•˜๊ณ  ์ œ์กฐ์ƒ์˜ ์–ด๋ ค์›€๋„ ์™„ํ™”ํ•  ์ˆ˜ ์žˆ๋‹ค.

* ease : <ํ†ต์ฆโˆ™๊ธด์žฅ ๋“ฑ>์„ ์™„ํ™”ํ•˜๋‹ค, <๋ฌธ์ œ ๋“ฑ>์„ ๊ฐœ์„ ํ•˜๋‹ค

โ€‹

As the company progresses with danuglipron, it continues to evaluate other experimental obesity treatments in its pipeline, demonstrating a long-term commitment.

โ€‹ํ™”์ด์ž๋Š” ๋‹ค๋ˆ„๊ธ€๋ฆฌํ”„๋ก ์˜ ์—ฐ๊ตฌ๋ฅผ ์ง„ํ–‰ํ•˜๋ฉด์„œ, ๊ฐœ๋ฐœ ์ค‘์ธ ๋‹ค๋ฅธ ์‹คํ—˜์ ์ธ ๋น„๋งŒ ์น˜๋ฃŒ์ œ๋„ ์ง€์†์ ์œผ๋กœ ํ‰๊ฐ€ํ•˜๊ณ  ์žˆ์–ด ์žฅ๊ธฐ์ ์œผ๋กœ ๊ฐœ๋ฐœ์— ์ž„ํ•˜๊ฒ ๋‹ค๋Š” ์˜์ง€๋ฅผ ๋‚ด๋น„์น˜๊ณ  ์žˆ๋‹ค.

* evaluate : โ‹ฏ์„ ํ‰๊ฐ€ํ•˜๋‹ค, ๊ฐ์ •ํ•˜๋‹ค

* experimental : <์ƒ๊ฐโˆ™๋ฐฉ๋ฒ• ๋“ฑ์ด> ์‹คํ—˜์ ์ธ, ์‹œํ—˜์ ์ธ

* be in the pipeline : <๊ณ„ํšโˆ™ํ–‰์‚ฌ ๋“ฑ์ด> ์ค€๋น„ ์ค‘์ด๋‹ค

* demonstrate : <๋Šฅ๋ ฅโˆ™์ž์งˆ ๋“ฑ>์„ ๋ณด์—ฌ์ฃผ๋‹ค, <๊ฐ์ • ๋“ฑ>์„ ํ‘œํ˜„ํ•˜๋‹ค

* commitment : (์กฐ์งโˆ™ํ™œ๋™์—์˜) ํ—Œ์‹ , ์ „๋…, (์•ฝ์†์— ๋”ฐ๋ฅธ) ์˜๋ฌด, ์ฑ…์ž„

 

 

โ€‹์˜์–ด๋ฅผ ๋”~์ž˜ํ•˜๋ ค๋ฉด ์ฑ…์„ ๊ตฌ๋งคํ•ด์„œ ์ฆ๊ฒ๊ฒŒ~์”ฌ๋‚˜๊ฒŒ~ํ•˜์„ธ์š”~
์ˆ ์ˆ ์ˆ  ์˜์–ด๋ง~์ž˜~ํ•˜์‹œ๋Š” ์ฒœ์‚ฌ๋‹˜๐Ÿ˜‡๋“ค ๋•๋ถ„์— ํ–‰๋ณตํ•ฉ๋‹ˆ๋‹ค~~
9์›” ๊ท€ํŠธ์˜ ๊ต์žฌ ๊ตฌ๋งค์ฒ˜~~~๐Ÿ’›๐Ÿงก๐Ÿ’›~~~

 

 

์œ„ ๋งํฌ๋กœ ๊ตฌ๋งค์‹œ ์ฟ ํŒกํŒŒํŠธ๋„ˆ์Šค์˜ ์ผํ™˜์œผ๋กœ ์ด์— ๋”ฐ๋ฅธ ์ผ์ •์•ก์˜ ์ˆ˜์ˆ˜๋ฃŒ๋ฅผ ์ œ๊ณต๋ฐ›์Šต๋‹ˆ๋‹ค~~~
์ฒœ์‚ฌ๐Ÿ˜‡๋‹˜๋“ค ๋•๋ถ„์— ์ด๋ฃจ์–ด์ง„ ์ˆ˜์ต ๋„ˆ๋ฌด๋‚˜ ๊ฐ์‚ฌํ•ฉ๋‹ˆ๋‹ค~~ 
๋•๋ถ„์— ์ปดํŒจ์…˜ ์•„์ด๋“ค์„ ๋„์šธ์ˆ˜ ์žˆ์–ด์„œ ํ–‰๋ณตํ•ฉ๋‹ˆ๋‹ค~๐Ÿ’›๐Ÿงก๐Ÿ’›